Article
Automated next-generation profiling of genomic alterations in human cancers.
Nature communications - 20 May 2022
Keefer Laurel A, White James R, Wood Derrick E, Gerding Kelly M R, Valkenburg Kenneth C, Riley David, Gault Christopher, Papp Eniko, Vollmer Christine M, Greer Amy, Hernandez James, McGregor Paul M, Zingone Adriana, Ryan Bríd M, Deak Kristen, McCall Shannon J, Datto Michael B, Prescott James L, Thompson John F, Cerqueira Gustavo C, Jones Siân, Simmons John K, McElhinny Abigail, Dickey Jennifer, Angiuoli Samuel V, Diaz Luis A, Velculescu Victor E, Sausen Mark
Abstract excerpt
The lack of validated, distributed comprehensive genomic profiling assays for patients with cancer inhibits access to precision oncology treatment. To address this, we describe elio tissue complete, which has been FDA-cleared for examination of 505 cancer-related genes. Independent analyses of clinically and biologically relevant sequence changes across 170 clinical tumor samples using MSK-IMPACT, FoundationOne,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.